Related Experiment Video

Updated: Jul 18, 2026

Examining BCL-2 Family Function with Large Unilamellar Vesicles
08:35

Examining BCL-2 Family Function with Large Unilamellar Vesicles

Published on: October 5, 2012

Concomitant inhibition of MDM2 and Bcl-2 protein function synergistically induce mitochondrial apoptosis in AML

Kensuke Kojima1, Marina Konopleva, Ismael J Samudio

  • 1Section of Molecular Hematology and Therapy, Department of Blood and Marrow Transplantation, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.

Cell Cycle (Georgetown, Tex.)
|December 19, 2006
PubMed

Insights

Combining Mdm2 inhibition with Bcl-2 inhibition synergistically induces apoptosis in acute myeloid leukemia (AML) cells. This dual-targeting strategy shows promise for AML therapy by overcoming resistance mechanisms and enhancing cell death.

Area of Science:

  • Molecular Biology
  • Cancer Research
  • Pharmacology

Background:

  • Disrupting the Mdm2-p53 interaction activates p53 signaling, promoting apoptosis in acute myeloid leukemia (AML).
  • Overexpression of Bcl-2, an antiapoptotic protein, can counteract Mdm2 inhibition-induced apoptosis in AML.
  • Inactivating antiapoptotic Bcl-2 proteins may enhance the effectiveness of Mdm2 inhibitors.

Purpose of the Study:

  • To investigate the therapeutic potential of combining Mdm2 inhibition (Nutlin-3a) with Bcl-2 inhibition (ABT-737) in AML.
  • To explore the synergistic effects and underlying mechanisms of this combined therapeutic approach.

Main Methods:

  • Utilized Nutlin-3a and ABT-737, inhibitors of Mdm2-p53 and Bcl-2 protein-protein interactions, respectively.
  • Assessed Bax conformational change and mitochondrial apoptosis induction in AML cells.
  • Analyzed cell cycle-specific effects and Bcl-2 protein levels and phosphorylation.

Main Results:

  • Nutlin-3a and ABT-737 demonstrated striking synergistic activity, inducing Bax conformational change and mitochondrial apoptosis in AML cells.
  • Nutlin-3a induced p53-mediated apoptosis primarily in S and G2/M cell cycle phases, while ABT-737 predominantly induced apoptosis in the G1 phase.
  • Complementary cell cycle targeting and lower Bcl-2 levels/activity in G1 cells contributed to the observed synergy.

Conclusions:

  • Combined targeting of Mdm2 and Bcl-2 proteins exhibits significant synergistic therapeutic promise in acute myeloid leukemia.
  • The differential cell cycle effects of Nutlin-3a and ABT-737 contribute to their combined efficacy.
  • This dual-inhibition strategy warrants further investigation for AML treatment.

More Related Videos

Cell Death Associated with Abnormal Mitosis Observed by Confocal Imaging in Live Cancer Cells15:53

Cell Death Associated with Abnormal Mitosis Observed by Confocal Imaging in Live Cancer Cells

Published on: August 21, 2013

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Cellular Injury V: Apoptosis and Autophagy01:22

Cellular Injury V: Apoptosis and Autophagy

Cells respond to damage and stress through highly coordinated processes that decide whether they survive or undergo controlled self-destruction. Two major pathways involved in this regulation are apoptosis, a type of programmed cell death, and autophagy, a survival mechanism that helps cells adapt to adverse conditions.ApoptosisApoptosis removes aged or injured cells to maintain tissue balance. During this process, the cell shrinks, chromatin condenses and fragments, and membrane-bound...